ClinicalTrials.gg
CompletedNCT01064882Updated Dec 9, 2011Results posted

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

A Phase 2 interventional study of bimatoprost ophthalmic solution 0.005% and bimatoprost ophthalmic solution 0.015% in Eyelash Hypotrichosis, sponsored by Allergan. Completed at 1 site in United States. Open to female participants aged 30 Years to 55 Years. Per ClinicalTrials.gov, last updated 2011-12-09.

Sponsored by Allergan (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
30 Years to 55 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Hypotrichosis by AbbVie — none open to participants now, none under way, none of them phase 3. Hypotrichosis · AbbVie.

Started
2010
with 1 other
Phase 2
Only one
of the 11
Registered
3rd of 11
by date

Among the 11 studies in Hypotrichosis by AbbVie, this one is one of 2 that started in 2010, is the only one in phase 2, and was the 3rd registered.

Hypotrichosis

24 studies on the registry are indexed under Hypotrichosis; 2 are open to participants now.

Browse Hypotrichosis studies →

Open to participants now

None of the 11 studies in Hypotrichosis by AbbVie is open now. The open studies under Hypotrichosis, anywhere →

Who these studies take

Of the 2 Hypotrichosis studies recruiting now, none set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 30 Years to 55 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Hypotrichosis by AbbVie as a file.
02

Study summary

This study will evaluate the safety and efficacy of bimatoprost ophthalmic solution 0.005% or 0.015% compared with bimatoprost ophthalmic solution 0.03% once-daily application to the upper eyelid margins in increasing eyelash prominence

03

Conditions studied

  • Eyelash Hypotrichosis

Browse trials for

04

Who can participate

Ages eligible
30 Years to 55 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female Caucasians between 30 and 55 years of age, with hypotrichosis (inadequate or not enough) of the eyelashes
  • Eyelash prominence assessment of minimal or moderate

Exclusion criteria

Exclusion Criteria:

  • Any eye disease or abnormality
  • Any permanent eyeliner or eyelash implants of any kind
  • Any ocular surgery, semi-permanent eyelash tint, or eyelash extension application during the 3 months prior to study entry
  • Any use of prescription eyelash growth products
  • Any use of over the counter eyelash growth products during the 6 months prior to baseline
  • Any use of treatments that may affect hair growth during the 6 months prior to baseline
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    bimatoprost ophthalmic solution 0.005%

    bimatoprost ophthalmic sterile solution 0.005%

    Drug: bimatoprost ophthalmic solution 0.005%

  • Experimental
    bimatoprost ophthalmic solution 0.015%

    bimatoprost ophthalmic sterile solution 0.015%

    Drug: bimatoprost ophthalmic solution 0.015%

  • Active comparator
    bimatoprost ophthalmic solution 0.03%

    bimatoprost ophthalmic solution 0.03%

    Drug: bimatoprost ophthalmic solution 0.03%

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Eyelash Length at Month 3

    Change from Baseline at Month 3 in eyelash length, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.

    Time frame: Baseline, Month 3

Secondary outcomes

  1. Change From Baseline in Upper Eyelash Thickness at Month 3

    Change from baseline in upper eyelash thickness/fullness at Month 3 was measured within 3 preset areas. Eyelash thickness/fullness was assessed across both eyes as an average of the 3 preset areas measured in millimeters squared (mm\^2). Changes from baseline to Month 3 represented by positive values indicated increased eyelash thickness, and changes from baseline represented by negative values indicated thinner eyelash thickness.

    Time frame: Baseline, Month 3

  2. Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3

    Change from baseline in upper eyelash darkness at Month 3 was determined by lash intensity within the spline (a narrow area approximately 5 pixels wide that bisects the area of interest). Upper eyelash darkness was measured in both eyes and averaged for analysis. Colors ranged from black=0 to white=255. Lower numbers on this continuum indicated darker colors. Therefore, a change from baseline to Month 3 represented by a negative value indicated increased eyelash darkening.

    Time frame: Baseline, Month 3

  3. Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3

    Percentage of subjects with a clinical response in overall eyelash prominence at Month 3 was measured using a 4-point GEA scale with the aid of the photonumeric guide. The scale ranges from 1 (minimal = worst) prominence to 4 (very marked = best)prominence. Eyelash prominence was assessed and graded by the investigator over both eyes. A clinical response was defined as at least a 1-grade increase in GEA score from baseline to Month 3.

    Time frame: Month 3

  4. Change From Baseline in Overall Eyelash Satisfaction at Month 3

    Change from baseline at Month 3 in question 3 "overall, how satisfied are you with your eyelashes?" Responses ranged from 1 (very unsatisfied = worst) to 5 (very satisfied = best). Individual responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.

    Time frame: Baseline, Month 3

  5. Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3

    Change from baseline in the CAP domain at Month 3 included responses to questions 7, 8, and 9. Responses to each question ranged from 1 (very much disagree = worst) to 5 (very much agree = best) with the minimum sum of the scores for the domain equal to 3 and the maximum sum of the scores for the domain equal to 15. Domain responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.

    Time frame: Baseline, Month 3

  6. Treatment Satisfaction Questionnaire Score at Month 3

    The Treatment Satisfaction Questionnaire at Month 3 consisted of 2 questions that collected information regarding subject satisfaction with the treatment overall. The questions assessed the likelihood that the subject would use the product, as well as the likelihood that the subject would recommend the product to family and/or friends, if it were available. The score was based on the responses to each question. Questions were answered on a 5-point scale ranging from 1 (very unlikely = worst) to 5 (very likely = best).

    Time frame: Month 3

07

Results

Posted Dec 9, 2011

Participant flow

Participant flow — Overall Study
MilestoneBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Started363434
Completed343232
Not completed222

Outcome measures

PrimaryChange From Baseline in Eyelash Length at Month 3

Change from Baseline at Month 3 in eyelash length, measured in millimeters (mm). Data from both eyes were averaged for each subject for analysis. Changes from baseline represented by positive values indicated longer length, and changes from baseline represented by negative values indicated shorter length.

Time frame:
Baseline, Month 3
Reported as:
Mean · millimeters (mm)
Change From Baseline in Eyelash Length at Month 3
millimeters (mm)Bimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Baseline5.65 ± 0.7635.68 ± 0.6135.95 ± 0.744
Change from Baseline at Month 30.74 ± 0.6840.92 ± 0.6681.36 ± 0.944
SecondaryChange From Baseline in Upper Eyelash Thickness at Month 3

Change from baseline in upper eyelash thickness/fullness at Month 3 was measured within 3 preset areas. Eyelash thickness/fullness was assessed across both eyes as an average of the 3 preset areas measured in millimeters squared (mm\^2). Changes from baseline to Month 3 represented by positive values indicated increased eyelash thickness, and changes from baseline represented by negative values indicated thinner eyelash thickness.

Time frame:
Baseline, Month 3
Reported as:
Mean · Millimeters squared (mm^2)
Change From Baseline in Upper Eyelash Thickness at Month 3
Millimeters squared (mm^2)Bimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Baseline12.75 ± 5.50214.67 ± 7.54013.69 ± 6.753
Change from Baseline at Month 34.50 ± 4.7605.64 ± 5.2388.48 ± 7.387
SecondaryChange From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3

Change from baseline in upper eyelash darkness at Month 3 was determined by lash intensity within the spline (a narrow area approximately 5 pixels wide that bisects the area of interest). Upper eyelash darkness was measured in both eyes and averaged for analysis. Colors ranged from black=0 to white=255. Lower numbers on this continuum indicated darker colors. Therefore, a change from baseline to Month 3 represented by a negative value indicated increased eyelash darkening.

Time frame:
Baseline, Month 3
Reported as:
Mean · Units on a Scale
Change From Baseline in Upper Eyelash Darkness (in Intensity Units) at Month 3
Units on a ScaleBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Baseline157.14 ± 22.814154.41 ± 21.065162.41 ± 17.321
Change from Baseline at Month 3-18.75 ± 23.276-26.55 ± 22.505-29.61 ± 20.443
SecondaryPercentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3

Percentage of subjects with a clinical response in overall eyelash prominence at Month 3 was measured using a 4-point GEA scale with the aid of the photonumeric guide. The scale ranges from 1 (minimal = worst) prominence to 4 (very marked = best)prominence. Eyelash prominence was assessed and graded by the investigator over both eyes. A clinical response was defined as at least a 1-grade increase in GEA score from baseline to Month 3.

Time frame:
Month 3
Reported as:
Number · Percentage of Subjects
Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 3
Percentage of SubjectsBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Percentage of Subjects With a Clinical Response in Overall Eyelash Prominence on the Global Eyelash Assessment (GEA) at Month 352.879.485.3
SecondaryChange From Baseline in Overall Eyelash Satisfaction at Month 3

Change from baseline at Month 3 in question 3 "overall, how satisfied are you with your eyelashes?" Responses ranged from 1 (very unsatisfied = worst) to 5 (very satisfied = best). Individual responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.

Time frame:
Baseline, Month 3
Reported as:
Mean · Scores on a Scale
Change From Baseline in Overall Eyelash Satisfaction at Month 3
Scores on a ScaleBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Baseline1.47 ± 0.5601.56 ± 0.6131.71 ± 0.524
Change from Baseline at Month 31.35 ± 1.3232.25 ± 1.3682.06 ± 0.840
SecondaryChange From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3

Change from baseline in the CAP domain at Month 3 included responses to questions 7, 8, and 9. Responses to each question ranged from 1 (very much disagree = worst) to 5 (very much agree = best) with the minimum sum of the scores for the domain equal to 3 and the maximum sum of the scores for the domain equal to 15. Domain responses at Month 3 were compared to baseline. Positive values at Month 3 indicated an improvement from baseline, and negative values indicated a worsening from baseline.

Time frame:
Baseline, Month 3
Reported as:
Mean · Scores on a Scale
Change From Baseline in the Confidence, Attractiveness, and Professionalism (CAP) Domain Scores at Month 3
Scores on a ScaleBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Baseline4.33 ± 2.0984.53 ± 1.8304.94 ± 2.029
Change from Baseline at Month 32.79 ± 3.1984.72 ± 3.7523.06 ± 2.526
SecondaryTreatment Satisfaction Questionnaire Score at Month 3

The Treatment Satisfaction Questionnaire at Month 3 consisted of 2 questions that collected information regarding subject satisfaction with the treatment overall. The questions assessed the likelihood that the subject would use the product, as well as the likelihood that the subject would recommend the product to family and/or friends, if it were available. The score was based on the responses to each question. Questions were answered on a 5-point scale ranging from 1 (very unlikely = worst) to 5 (very likely = best).

Time frame:
Month 3
Reported as:
Mean · Scores on a Scale
Treatment Satisfaction Questionnaire Score at Month 3
Scores on a ScaleBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
If Avail, How Likely Would You Continue to Use It?4.1 ± 1.214.2 ± 1.144.1 ± 0.93
If Avail, How Likely Would You Recommend It?4.1 ± 1.264.2 ± 1.074.4 ± 0.61

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bimatoprost Ophthalmic Solution 0.005%—0/36 (0%)0/36 (0%)
Bimatoprost Ophthalmic Solution 0.015%—1/34 (2.9%)7/34 (20.6%)
Bimatoprost Ophthalmic Solution 0.03%—0/34 (0%)2/34 (5.9%)
Most frequent serious events
Most frequent serious events
EventBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
AppendicitisInfections and infestations0/361/340/34
Most frequent other events
Most frequent other events
EventBimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%
Eyelids PruritusEye disorders0/363/342/34
Eyelid PainEye disorders0/362/340/34
Upper Respiratory Tract InfectionInfections and infestations0/362/340/34

Baseline characteristics

Age Continuous
Age Continuous(years)Bimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%Total
Mean46.9 (32 to 55)45.4 (33 to 55)46.7 (31 to 55)46.3 (31 to 55)
Sex: Female, Male
Sex: Female, Male(Participants)Bimatoprost Ophthalmic Solution 0.005%Bimatoprost Ophthalmic Solution 0.015%Bimatoprost Ophthalmic Solution 0.03%Total
Female363434104
Male0000
08

Study locations

1 site
  • San Diego, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2011, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2010
First posted
Feb 9, 2010
Start
Mar 2010
Primary completionActual
Jul 2010
CompletionActual
Jul 2010
Results first posted
Dec 9, 2011
Last update
Dec 9, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01064882
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 9, 2010
Start date
Mar 2010
Primary completion
Jul 2010
Completion
Jul 2010
Results posted
Dec 9, 2011
Last update
Dec 9, 2011

Study contacts

Medical Director
study director · Allergan
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bimatoprost Ophthalmic Solution

Start the discussion